Pancreatic ductal adenocarcinoma remains highly resistant to treatment because of a dense and suppressive tumor environment that blocks both drugs and immune cells. Researchers describe this tumor microenvironment as “cold,” meaning it does not naturally support strong immune activity.
A major component of this barrier is the tumor stroma, which is made up of several supportive cell types rather than just structural tissue. Cancer-associated fibroblasts help build a thick collagen network that physically shields the tumor, while other fibroblast types release inflammatory signals that suppress immune responses or encourage regulatory immune cells that dampen activity.
Additional immune cells inside the tumor, including myeloid-derived suppressor cells and M2-type macrophages, further weaken anti-tumor immunity by depleting nutrients and shutting down T cells. Dendritic cells, which normally alert the immune system, often become dysfunctional in this environment.
Because standard immunotherapy drugs have shown limited success, new approaches are being explored, including mRNA-based cancer vaccines and engineered natural killer (CAR-NK) cell therapies designed to bypass tumor defenses and improve immune targeting.